Avricore Health Expands HealthTab in UK
Analysis based on 8 articles · First reported Apr 21, 2026 · Last updated Apr 21, 2026
The expansion of Avricore Health's HealthTab platform in the United Kingdom is expected to positively impact the company's revenue and profitability, with a target return to profitability by Q3 2027. This growth in point-of-care testing within community pharmacies, supported by the United Kingdom — National Health Service, signifies a broader trend in healthcare delivery that could benefit other companies in the medical diagnostics and pharmacy services sectors.
Avricore Health is significantly expanding its HealthTab point-of-care testing platform across the United Kingdom, having already screened over 3,500 patients in London pharmacies. The company has published a strategic update, 'The Path Forward,' detailing its plan for broader regional and national expansion, targeting 500 or more active UK locations by mid-2027. HealthTab has gained traction with the United Kingdom — National Health Service, including collaborations with United Kingdom — Barts Health NHS Trust and independent evaluation by UCLPartners. The platform is expanding its test menu, with HbA1c testing for diabetes launched in Q1 2026 and UACR kidney function testing planned for Q3 2026. The company anticipates monthly subscription revenue to begin in the second half of 2026 and aims for profitability by Q3 2027, supported by regulatory shifts in England that empower pharmacists as independent prescribers.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard